How will your approach to screening and diagnosis of early dementia change given newly available therapies for early Alzheimer's disease?   

As it stands, it is not recommended to screen asymptomatic patients for the proteins seen in Alzheimer’s disease outside of clinical trials (i.e., AHEAD 3-45). However, with the emergence of new treatment options in the clinic, I foresee an influx of patients with cognitive symptoms who need a...

At this time (and hopefully, not for long), I do not screen those who have no cognitive complaints at all. It is difficult to manage those patients at this point except for frequent follow-ups. It is not easy to convince patients who come to see you for non-cognitive symptoms that they should have a...

Though we are close to starting infusions at UVA, we have not really started yet. So, we are still working on the best process to expedite cognitive testing and dementia workup, for all new patients that clinically are diagnosed with mild cognitive impairment and mild dementia. We also follow patien...

Blood-based biomarkers offer great versatility, providing comprehensive information that is both cost-effective and readily available. Martin Sadowski, MD, a professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine, stated in an interview with NeurologyLive; "They ...

All patients will get an MMSE or MoCA. All patients will also get an FAQ, which is required by the Medicare registry. All patients will need a new MRI, a confirmation of amyloid status, and APOE testing to guide discussions about their personal risk. In the past, confirmation of amyloid status and A...